Fig. 1: The Laser in Glaucoma and ocular Hypertension Trial (LiGHT) showed that at 3 years follow up initial selective laser trabeculoplasty followed by conventional medical therapy as required to reach target IOP was more cost effective than medical therapy alone for patients with ocular hypertension or primary open angle glaucoma. | Eye

Fig. 1: The Laser in Glaucoma and ocular Hypertension Trial (LiGHT) showed that at 3 years follow up initial selective laser trabeculoplasty followed by conventional medical therapy as required to reach target IOP was more cost effective than medical therapy alone for patients with ocular hypertension or primary open angle glaucoma.

From: Correction to: Infographic: Laser in Glaucoma and Ocular Hypertension Trial (LiGHT)

Fig. 1

IOP intraocular pressure, OHT ocular hypertension, POAG primary open angle glaucoma, SLT selective laser trabeculoplasty, VA visual acuity, VF visual field. Reference to original study: Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicenter randomised controlled trial. Lancet. 2019;393(10180):1505–16.

Back to article page